Literature DB >> 6644314

Central catecholamine metabolism in vivo and the cognitive and motor deficits in Parkinson's disease.

J J Mann, M Stanley, R D Kaplan, J Sweeney, A Neophytides.   

Abstract

Cerebrospinal fluid levels of homovanillic acid (HVA) in unmedicated patients with Parkinson's disease were 45% of levels in control subjects. Levels of 3-methoxy-4-hydroxyphenylglycol (MHPG) and platelet monoamine oxidase activity (MAO) did not differ. Within the Parkinson's disease group platelet MAO B activity correlated with HVA (an MAO B substrate) but not MHPG (an MAO A substrate). A mild global dementia was found that did not correlate with the more severe motor deficit. There was a negative correlation between the motor deficit and HVA levels but not with MHPG. Cognitive functioning correlated positively with platelet MAO, and the ratio of HVA to MHPG levels and negatively with MHPG alone. It is postulated that dopaminergic and noradrenergic activity or the functional balance between these systems may contribute to the observed cognitive dysfunction.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6644314      PMCID: PMC1027603          DOI: 10.1136/jnnp.46.10.905

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  30 in total

1.  Brief objective measures for the determination of mental status in the aged.

Authors:  R L KAHN; A I GOLDFARB; M POLLACK; A PECK
Journal:  Am J Psychiatry       Date:  1960-10       Impact factor: 18.112

2.  Dementia in Parkinson's disease.

Authors:  R J Marttila; U K Rinne
Journal:  Acta Neurol Scand       Date:  1976-11       Impact factor: 3.209

3.  Parkinson's disease, cerebral arteriosclerosis, and senile dementia. Clinical features and response to levodopa.

Authors:  J D Parkes; C D Marsden; J E Rees; G Curzon; B D Kantamaneni; R Knill-Jones; A Akbar; S Das; M Kataria
Journal:  Q J Med       Date:  1974-01

4.  The effect of L-dopa on monoamine metabolites in Parkinson's disease.

Authors:  M H van Woert; M B Bowers
Journal:  Experientia       Date:  1970

5.  Relationship of monoamine metabolites in human cerebrospinal fluid to age.

Authors:  M B Bowers; F A Gerbode
Journal:  Nature       Date:  1968-09-21       Impact factor: 49.962

6.  Patterns of declining memory.

Authors:  J G Gilbert; R F Levee
Journal:  J Gerontol       Date:  1971-01

7.  Parkinsonism: onset, progression and mortality.

Authors:  M M Hoehn; M D Yahr
Journal:  Neurology       Date:  1967-05       Impact factor: 9.910

8.  Monoamine metabolism in human brain.

Authors:  D S Robinson; T L Sourkes; A Nies; L S Harris; S Spector; D L Bartlett; I S Kaye
Journal:  Arch Gen Psychiatry       Date:  1977-01

9.  Dopamine receptors in the Parkinsonian brain.

Authors:  U K Rinne; P Lönnberg; V Koskinen
Journal:  J Neural Transm       Date:  1981       Impact factor: 3.575

10.  Molecular biology of neurological and psychiatric disorders. I. Effect of parkinsonism, age, sex and L-dopa on platelet monoamine oxidase.

Authors:  E A Zeller; B Boshes; J Arbit; M Bieber; E R Blonsky; M Dolkart; S V Huprikar
Journal:  J Neural Transm       Date:  1976       Impact factor: 3.575

View more
  8 in total

1.  Platelet monoamine oxidase B activity in parkinsonian patients.

Authors:  U Bonuccelli; P Piccini; P Del Dotto; G M Pacifici; G U Corsini; A Muratorio
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-10       Impact factor: 10.154

2.  Platelet phenolsulphotransferase activity, monoamine oxidase activity and peripheral-type benzodiazepine binding in demented patients.

Authors:  P Bongioanni; M Donato; M Castagna; F Gemignani
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

3.  Decreased beta-phenylethylamine in CSF in Parkinson's disease.

Authors:  G Zhou; H Shoji; S Yamada; T Matsuishi
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-12       Impact factor: 10.154

4.  Differential response of the central noradrenergic nervous system to the loss of locus coeruleus neurons in Parkinson's disease and Alzheimer's disease.

Authors:  Pamela J McMillan; Sylvia S White; Allyn Franklin; J Lynne Greenup; James B Leverenz; Murray A Raskind; Patricia Szot
Journal:  Brain Res       Date:  2010-12-11       Impact factor: 3.252

5.  Transgenic Mice Expressing Human α-Synuclein in Noradrenergic Neurons Develop Locus Ceruleus Pathology and Nonmotor Features of Parkinson's Disease.

Authors:  Laura M Butkovich; Madelyn C Houser; Termpanit Chalermpalanupap; Kirsten A Porter-Stransky; Alexa F Iannitelli; Jake S Boles; Grace M Lloyd; Alexandra S Coomes; Lori N Eidson; Maria Elizabeth De Sousa Rodrigues; Danielle L Oliver; Sean D Kelly; Jianjun Chang; Nora Bengoa-Vergniory; Richard Wade-Martins; Benoit I Giasson; Valerie Joers; David Weinshenker; Malú Gámez Tansey
Journal:  J Neurosci       Date:  2020-08-31       Impact factor: 6.167

6.  Prediction of changes in memory performance by plasma homovanillic acid levels in clozapine-treated patients with schizophrenia.

Authors:  Tomiki Sumiyoshi; A Roy; C-H Kim; K Jayathilake; M A Lee; C Sumiyoshi; H Y Meltzer
Journal:  Psychopharmacology (Berl)       Date:  2004-06-04       Impact factor: 4.530

Review 7.  Cerebrospinal fluid biochemical studies in patients with Parkinson's disease: toward a potential search for biomarkers for this disease.

Authors:  Félix J Jiménez-Jiménez; Hortensia Alonso-Navarro; Elena García-Martín; José A G Agúndez
Journal:  Front Cell Neurosci       Date:  2014-11-11       Impact factor: 5.505

8.  High-Fat Diet-Induced Weight Gain, Behavioral Deficits, and Dopamine Changes in Young C57BL/6J Mice.

Authors:  Jian Han; Pragya Nepal; Anuoluwapo Odelade; Frederick D Freely; Destiny M Belton; Joseph L Graves; Antoniette M Maldonado-Devincci
Journal:  Front Nutr       Date:  2021-01-20
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.